Updates are available Correction dated 2023-08-14
Click to view Correction: https://doi.org/10.1186/s13063-023-07471-1
-
Authors
Pradat, Pierre http://orcid.org/0000-0001-6331-8321
Pantel, Solene
Maynard, Marianne
Lalande, Laure
Thevenon, Sylvie
Adam, Rene
Allard, Marc-Antoine
Robin, Fabien
Rayar, Michel
Boleslawski, Emmanuel
Scatton, Olivier
Chirica, Mircea
Faitot, François
Bachellier, Philippe
Soubrane, Olivier
Mohkam, Kayvan
Mabrut, Jean-Yves
Lesurtel, Mickaël
-
Funding
Funding for this research was provided by:
PHRCN (PHRCN-18-0053)
- License Information
-
More Information
Article History
Received: 27 March 2023
Accepted: 22 May 2023
First Online: 6 June 2023
Change Date: 14 August 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13063-023-07471-1
Declarations
:
: The HOPEext study protocol was approved by a human research ethics committee (Comité de Protection des Personnes Ile de France III) on June 5, 2019, under the reference number 3688-I. The trial also received approval from the French regulatory agency (Agence National de Sécurité du Médicament) on June 20, 2019 (190004B-13). Written informed consent will be obtained from all participants.
: A copy of the informed consent form is available as Supplementary Material .
: The authors declare they have no competing interests.
